0001104659-25-065009.txt : 20250702 0001104659-25-065009.hdr.sgml : 20250702 20250702070547 ACCESSION NUMBER: 0001104659-25-065009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250701 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250702 DATE AS OF CHANGE: 20250702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Astrana Health, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] ORGANIZATION NAME: 07 Trade & Services EIN: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 251098319 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: Apollo Medical Holdings, Inc. DATE OF NAME CHANGE: 20080715 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm2519514d1_8k.htm FORM 8-K
false 0001083446 0001083446 2025-07-01 2025-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 1, 2025

 

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)

 

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

 

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ASTH The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

 

   

 

 

Item 1.01Entry into a Material Definitive Agreement.

 

The disclosure set forth under Item 2.01 of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 1.01.

 

Item 2.01Completion of Acquisition or Disposition of Assets.

 

On July 1, 2025, Astrana Health, Inc. (the “Company”) completed its previously announced acquisition (the “Closing”) of all of the outstanding equity interests of Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center) and Prospect Health Plan, Inc., and substantially all the assets of certain direct and indirect subsidiaries of PHP Holdings, LLC (“PHPH”), pursuant to the Asset and Equity Purchase Agreement (the “Purchase Agreement”), dated November 8, 2024, by and among the Company and certain direct and indirect subsidiaries party thereto, PHPH, PHS Holdings, LLC (“PHS”), Prospect Intermediate Holdings, LLC (“PIH” and, together with PHPH and PHS, the “Prospect Equity Sellers”), certain other related entities party thereto (such entities, the “Prospect Asset Sellers” and, together with the Prospect Equity Sellers, the “Sellers”) and Prospect Medical Holdings, Inc. (“Prospect”), as Seller Representative (such acquisition, the “Transaction”).

 

In connection with the Closing, on July 1, 2025, the Company and the Sellers entered into a letter agreement (the “Letter Agreement”) intended to address and reconcile post-Closing claims, matters, and obligations between the parties, including a reduction in the aggregate purchase price from $745.0 million to $707.9 million and the removal of certain post-Closing purchase price adjustments and related escrow. The Company and Sellers also entered into certain ancillary agreements, including a transition services agreement pursuant to which the Sellers will provide certain transition services to the Company on a post-Closing basis.

 

The aggregate purchase price paid at the Closing consisted of $707.9 million in cash and the assumption of certain identified liabilities of the Sellers. To finance the Transaction, the Company used $707.9 in proceeds from a five-year delayed draw term loan credit facility of up to $745 million pursuant to the Second Amended and Restated Credit Agreement, dated as of February 26, 2025, by and among the Company, as borrower, the lenders from time to time party thereto, and Truist Bank, as administrative agent for the lenders, as issuing bank and as swingline lender (the “Second Amended and Restated Credit Agreement”).

 

The above descriptions of the Purchase Agreement, the Letter Agreement, and the Second Amended and Restated Credit Agreement do not purport to be complete and are subject to, and qualified in their entirety by, the full text of the Purchase Agreement, a copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2024, the full text of the Letter Agreement, and the full text of the Second Amended and Restated Credit Agreement, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 27, 2025, each of which is incorporated herein by reference.

 

The Purchase Agreement and the Letter Agreement have been included in this Current Report to provide investors and security holders with information regarding the terms of the Transaction. They are not intended to provide any other factual information about the Company, the Sellers, Prospect or any of the other parties to the Transaction or the equity to be purchased in the Transaction or such Purchase Agreement or Letter Agreement. The representations, warranties, covenants and agreements contained in the Purchase Agreement and Letter Agreement are made only for purposes of such agreements and as of specific dates indicated therein, are solely for the benefit of the parties thereto, may be subject to limitations agreed upon by the parties (including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the appliable agreement instead of establishing these matters as facts) and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors and security holders. Company investors and security holders should not rely on the representations, warranties, covenants and agreements or any descriptions thereof as characterizations of the actual state of facts or condition of the Company, the Sellers, Prospect or any of the other parties to the Transaction. Moreover, information concerning the subject matter of the representations and warranties may change after the date of such agreements, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On July 2, 2025, the Company issued a press release announcing the Closing, which, among other things, reaffirmed the Company’s second quarter guidance and updated the Company’s full-year 2025 revenue and adjusted EBITDA guidance. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report.

 

The preliminary financial results and forecasts included in the press release are based on assumptions and estimates made by the Company’s management and currently available information and are inherently uncertain and subjective. The preliminary financial results and forecasts do not take into account any events occurring after the date they were prepared. As a result, there can be no assurance that the projected results will be realized or that actual results will not be higher or lower than projected. The Company does not have an obligation to update the forecasts at any time in the future. The preliminary financial results and forecasts are unaudited and the audited financials may differ from these numbers in material respects.

 

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 7.01Regulation FD Disclosure.

 

The disclosure set forth under Item 2.02 of this Current Report is incorporated by reference into this Item 7.01.

 

The information contained in this Item 7.01 of this Current Report, including the exhibit referenced herein, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

 

Forward-Looking Statements

 

This Current Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include words such as “forecast,” “guidance,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “seeks,” “should,” or “will,” or the negative of these words or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in each such statement. A number of important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including, but not limited to, risks arising from the diversion of management’s attention from the Company’s ongoing business operations, an increase in the amount of costs, fees and expenses and other charges related to the Transaction described in this Current Report, risks of disruption to the Company’s business as a result of Closing, risks that the Transaction disrupts current plans and operations of the Company or Sellers and potential difficulties in employee retention as a result of the Transaction, the Company’s ability to pay the interest and principal on the Second Amended and Restated Credit Agreement, and the Company’s ability to implement business plans, forecasts and other expectations after Closing, realize the intended benefits of the Transaction, and identify and realize additional opportunities following the Transaction, as well as the other risks and uncertainties identified in filings by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as may be amended or supplemented by additional risk factors set forth in subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. The Company does not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any other document, whether as a result of new information, future events, or otherwise, except as may be required by any applicable securities laws.

 

 

 

 

Item 9.01Financial Statements and Exhibits.

 

(a)       Financial Statements of Businesses Acquired.

 

The financial statements required by this item are not being filed herewith. To the extent such information is required by this item, it will be filed with the SEC by amendment to this Current Report no later 71 days after the date on which this Current Report is required to be filed.

 

(b)       Pro Forma Financial Information.

 

The pro forma financial information required by this item is not being filed herewith. To the extent such information is required by this item, it will be filled with the SEC by amendment to this Current Report no later than 71 days after the date on which this Current Report is required to be filed.

 

(d)        Exhibits.

 

Exhibit
No.		   Description
2.1*   Asset and Equity Purchase Agreement, dated November 8, 2024, by and among Astrana Health, Inc., PHP Holdings, LLC, PHS Holdings, LLC, Prospect Intermediate Holdings, LLC, each of the entities set forth on Schedule C of the agreement, and Prospect Medical Holdings, Inc. (incorporated herein by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 8, 2024).
10.1*   Second Amended and Restated Credit Agreement, dated as of February 26, 2025, by and among Astrana Health, Inc., as Borrower, the Lenders from time to time party thereto, and Truist Bank, as administrative agent for the Lenders, as issuing bank and as swingline lender (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on February 27, 2025).
99.1   Press Release dated July 2, 2025
104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

 

* Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company agrees to furnish a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ASTRANA HEALTH, INC.
   
Date: July 2, 2025 By: /s/ Brandon K. Sim
  Name: Brandon K. Sim
  Title: Chief Executive Officer and President

 

 

 

 EX-99.1 2 tm2519514d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Astrana Health Announces Closing of Prospect Health Acquisition

 

ALHAMBRA, Calif., July 2, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced it closed the acquisition of Prospect Health on July 1st, 2025.

 

Prospect Health is a value-based, integrated care delivery network which coordinates the delivery of high-quality care for all. With a network of over 11,000 providers across Southern California, Texas, Arizona, and Rhode Island in its medical groups, Prospect enables providers to deliver payer-agnostic, patient-centered care to approximately 600,000 members across Medicare Advantage, Medicaid, and Commercial lines of business. Prospect Health also operates a California Restricted Knox-Keene-licensed health plan, a management services organization, a specialty pharmacy, and a fully-accredited acute care hospital.

 

The Company completed the acquisition of Prospect Health for a total purchase price of $708 million, a reduction from the originally announced $745 million in accordance with the terms of the executed Purchase Agreement. The updated purchase price underscores the Company’s commitment to disciplined capital deployment, while maintaining full conviction in the value creation potential of the asset. The acquisition of Prospect Health will deepen Astrana’s capabilities in providing access to high-quality and high-value care to communities across the country.

 

“We are excited to welcome Prospect Health’s physicians, providers, and team members to Astrana Health,” said Brandon Sim, President and CEO of Astrana. “Together, we will further accelerate our mission to drive consistent, coordinated, high-quality patient outcomes at scale, ultimately driving greater value across the healthcare ecosystem.”

 

Astrana continues to expect Prospect Health to contribute approximately $1.2 billion in total revenue and $81 million in adjusted EBITDA on a full-year basis, as previously announced. The Company also continues to anticipate realizing between $12 million to $15 million of synergies over the next twelve to eighteen months.

 

To reflect the half-year contribution from Prospect, Astrana is updating its full-year 2025 guidance to total revenue between $3.1 billion and $3.3 billion and adjusted EBITDA between $215 million and $225 million. In addition, the Company is also reiterating its second quarter, 2025 guidance.

 

With the close of the transaction, Astrana will now have approximately $700 million of net debt on its consolidated balance sheet. Management remains committed to reducing the Company’s net leverage ratio to below 2.5x over the next twelve to eighteen months.

 

Truist Securities led a syndicate of banks who provided a term loan used to finance the acquisition of Prospect Health. J.P. Morgan served as exclusive financial advisor to Astrana in connection with the transaction.

 

About Astrana Health

 

Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.

 

 

 

 

Today, Astrana supports more than 20,000 providers and over 1.6 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.

 

FOR MORE INFORMATION, PLEASE CONTACT:
Grant Hesser, Investor Relations
grant.hesser@astranahealth.com

  

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include words such as “forecast,” “guidance,” “projects,” “estimates,” “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “seeks,” “should,” or “will,” or the negative of these words or similar words. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in each such statement. A number of important factors could cause actual results to differ materially from those included within or contemplated by the forward-looking statements, including, but not limited to, risks arising from the diversion of management’s attention from the Company’s ongoing business operations, an increase in the amount of costs, fees and expenses and other charges related to the acquisition transaction described in this press release (the “Transaction”), risks of disruption to the Company’s business as a result of the closing of the acquisition, risks that the Transaction disrupts current plans and operations of the Company or sellers and potential difficulties in employee retention as a result of the Transaction, the Company’s ability to pay the interest and principal on the Second Amended and Restated Credit Agreement, and the Company’s ability to implement business plans, forecasts and other expectations after Closing, realize the intended benefits of the Transaction, and identify and realize additional opportunities following the Transaction, as well as the other risks and uncertainties identified in filings by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as may be amended or supplemented by additional risk factors set forth in subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. The Company does not undertake any responsibility to update any of these factors or to announce publicly any revisions to any of the forward-looking statements contained in this or any other document, whether as a result of new information, future events, or otherwise, except as may be required by any applicable securities laws.

 

The preliminary financial results and forecasts are based on assumptions and estimates made by Astrana’s management and currently available information and are inherently uncertain and subjective. The preliminary financial results and forecasts do not take into account any events occurring after the date they were prepared. As a result, there can be no assurance that the projected results will be realized or that actual results will not be higher or lower than projected. Astrana does not have an obligation to update the forecasts at any time in the future. The preliminary financial results and forecasts are unaudited and the audited financials may differ from these numbers in material respects.

 

Use of Non-GAAP Financial Measures

 

This press release contains the non-GAAP financial measures such as Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income, and net leverage ratio, of which the most directly comparable financial measure presented in accordance with GAAP is total debt and net income. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. The Company defines net leverage ratio as net debt over Adjusted EBITDA. Net debt is defined as current and non-current debt, operating leases, and finance leases, less cash and cash equivalents and marketable securities. The Company uses net leverage ratio for financial and operational decision-making and debt management.

 

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate Adjusted EBITDA and net leverage ratio differently, limiting the usefulness of these measures for comparative purposes. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The Company has not provided a quantitative reconciliation of applicable non-GAAP measures, such as the projected Adjusted EBITDA, to the most comparable GAAP measure, such as net income, on a forward-looking basis within this press release because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that cannot be calculated. These items, which could materially affect the computation of forward-looking GAAP net income are inherently uncertain and depend on various factors, some of which are outside of the Company’s control. 

 

 

 

 EX-101.SCH 3 asth-20250701.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 asth-20250701_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 asth-20250701_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Cover
Jul. 01, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 01, 2025
Entity File Number 001-37392
Entity Registrant Name ASTRANA HEALTH, INC.
Entity Central Index Key 0001083446
Entity Tax Identification Number 95-4472349
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1668 S. Garfield Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91801
City Area Code 626
Local Phone Number 282-0288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ASTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports asth-20250701.xsd asth-20250701_lab.xml asth-20250701_pre.xml tm2519514d1_8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2519514d1_8k.htm": { "nsprefix": "ASTH", "nsuri": "http://apollomed.net/20250701", "dts": { "schema": { "local": [ "asth-20250701.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "labelLink": { "local": [ "asth-20250701_lab.xml" ] }, "presentationLink": { "local": [ "asth-20250701_pre.xml" ] }, "inline": { "local": [ "tm2519514d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://apollomed.net/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2519514d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-07-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2519514d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://apollomed.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-25-065009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-25-065009-xbrl.zip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end XML 16 tm2519514d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2025-07-01 2025-07-01 iso4217:USD shares iso4217:USD shares false 0001083446 8-K 2025-07-01 ASTRANA HEALTH, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock ASTH NASDAQ false